Search

Displaying results 3081 - 3090 of 8517 in total
  1. Drug

    Desmoteplase

    go.drugbank.com/drugs/DB04925
    Investigational

    When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting. … Desmoteplase is a recombinant form of vampire bat DSPA (Salivary plasminogen activator alpha 1).

  2. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

  3. Drug

    Sorafenib

    go.drugbank.com/drugs/DB00398
    ApprovedInvestigational

    Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approve...

  4. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. … [A179689] Bremelanotide was granted FDA approval on 21 June 2019.[L9635]

  5. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.

  6. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. … It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]

  7. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial grow...

  8. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    In Canada, it is marketed as ONE-ALPHA, which manages hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in adults with chronic renal failure.

  9. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.

  10. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients